Osteoporosis and diabetes

Current Diabetes Reports

Volumn 3, Issue 1, 2003, Pages 37-42

  Chau, Diane L ^a   Edelman, Steven V ^b   Chandran, Manju ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACTONE; ALENDRONIC ACID; ANABOLIC AGENT; ANDROGEN; ANTICONVULSIVE AGENT; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; ESTROGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; MEDROXYPROGESTERONE ACETATE; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RETINOL; RISEDRONIC ACID; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STEROID; TROGLITAZONE; VITAMIN D; ZOLEDRONIC ACID;

BLOOD CLOTTING DISORDER; BLOOD GLUCOSE MONITORING; BREAST CANCER; CALCIUM INTAKE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG MECHANISM; DRUG POTENCY; ETHNIC DIFFERENCE; EXERCISE; FRACTURE; GLUCOSE METABOLISM; HEART DISEASE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; LOW DRUG DOSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OSTEOPOROSIS; PREVALENCE; REVIEW; RISK FACTOR; SCREENING TEST; SEX RATIO; SMOKING; STROKE; UNITED STATES; FEMALE; GLUCOSE BLOOD LEVEL; MALE; METABOLISM; PREGNANCY;

BLOOD GLUCOSE; CALCIUM, DIETARY; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; EXERCISE; FEMALE; HUMANS; MALE; OSTEOPOROSIS; PREGNANCY;

EID: 0037316808     PISSN: 15344827     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11892-003-0051-8     Document Type: Review

References (49)

1. World Health Organization: Assessment of Fracture Risk and Its Application to Screening for Postmenopausal Osteoporosis Report of a WHO study group. Geneva: World Health Organization; 1994 (Tech. Rep. Ser., no. 843).
2. Looker AC, Johnston CC Jr, Wahner HW, et al.: Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res 1995, 10:796-802.
3. Ray NF, Chan JK, Thamer M, Melton LJ III: Medical expenditures for the treatment of osteoporotic fracture in the United States in 1995: report from the National Osteoporosis Foundation. J Bone Miner Res 1997, 12:24-35.
4. Wu F, Mason B, Horne A, et al.: Fractures between the ages of 20 and 50 years increase women's risk of subsequent fractures. Arch Intern Med 2002, 162:33-36.
5. Siris ES, Miller PD, Barrett-Connor E, et al.: Identification and fracture outcomes of undiagnosed low bone mineral density in postmenopausal women: results from the National Osteoporosis Risk Assessment. JAMA 2001, 286:2815-2822.
6. Cooper C, Atkinson EJ, Jacobsen SJ, et al.: Population-based study of survival after osteoporotic fractures. Am J Epidemiol 1993, 137:1001-1005.
7. Nightingale S, Holmes J, Mason J, House A: Psychiatric illness and mortality after hip fracture. Lancet 2001, 357:1264-1264.
8. Risk assessment. http://www.nof.org/physguide/ risk_assessment.htm.
9. Forsen L, Meyer HE, Midthjell K, Edna TH: Diabetes mellitus and the incidence of hip fracture: results from the Nord-Trondelag Health Survey. Diabetologia 1999, 42:920-925.
10. Nicodemus KK, Folsom AR: Type 1 and type 2 diabetes and incident hip fractures in postmenopausal women. Diabetes Care 2001, 24:1192-1197.
11. Bouillon R: Diabetic bone disease. Calcif Tissue Int 1991, 49:155-160.
12. Ivers RQ, Cumming RG, Mitchell P, Peduto AJ: Diabetes and risk of fracture: the Blue Mountains Eye Study. Diabetes Care 2001, 24:1198-2003.
13. Piepkorn B, Kann P, Forst T, et al.: Bone mineral density and bone metabolism in diabetes mellitus. Horm Metab Res 1997, 29:584-591.
14. Aoyagi K, Ross PD, Davis JW, et al.: Falls among community-dwelling elderly in Japan. J Bone Miner Res 1998, 13:1468-1474.
15. Vogt MT, Cauley JA, Kuller LH, Nevin MC: Bone mineral density and blood flow to the lower extremities. J Bone Miner Res 1997, 12:283-289.
16. Schwartz AV, Sellmeyer DE, Ensrud KE, et al.: Older women with diabetes have an increased risk of fractures: a prospective study. J Clin Endocrinol Metab 1997, 86:32-38.
17. Gregorio F, Cristallini S, Santeusanio F, et al.: Osteopenia associated with non-insulin-dependent diabetes mellitus: what are the causes? Diabetes Res Clin Pract 1994, 23:43-54.
18. Okazaki R, Totsuka Y, Hamano K, et al.: Metabolic improvement of poorly controlled non insulin dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 1997, 82:2915-2920.
19. Chau DL, Mulvihill MM, Moore TR, et al.: Postpartum bone loss in Latino women with prior gestational diabetes. J Invest Med 2002, 50:71A.
20. Chau D, Edelman SV: Clinical management of diabetes in the elderly. Clin Diabetes 2001, 19:172-174.
21. Kannus P, Parkkari J, Niemi S, et al.: Prevention of hip fracture in elderly people with use of a hip protector. N Engl J Med 2000, 343:1506-1513.
22. Luckey MM: Evaluation of postmenopausal osteoporosis. In In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, edn 4. Edited by Fayus MJ. Philadelphia, PA: Lippincott, Williams, and Wilkins; 1999:273-277.
23. Marcus R: Role of exercise in preventing and treating osteoporosis. Rheum Dis Clin North Am 2001, 27:131-141.
24. Lane JM, Nydick M: Osteoporosis: current modes of prevention and treatment. J Am Orthop Surg 1999, 7:19-31.
25. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. Writing Group for the PEPI Trial [no authors listed]. JAMA 1996, 276:1389-1396.
26. Effects of menopause and estrogen or hormone replacement therapy in women with diabetes mellitus (Consensus Opinion). The North American Menopause Society [no authors listed]. Menopause 2000, 7:87-95.
27. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. Writing Group for the Women's Health Initiative Investigators [no authors listed]. JAMA 2002, 288:321-332.
28. Francis RM: Androgen replacement in aging men. Calcif Tissue Int 2001, 69:235-238.
29. Notelovitz M: Androgen effects on bone and muscle. Fertil Steril 2002, 77(suppl 4):34-41.
30. Raloxifene hydrochloride tablet [package insert]. Indianapolis, IN: Eli Lilly and Co.; 2000.
31. Ettinger B, Black DM, Mitlak BH, et al.: Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. (Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators). JAMA 1999, 282:637-645.
32. Taranta A, Brama M, Teti A, et al.: The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro. Bone 2002, 30:368-376.
33. Andersson B, Johannsson G, Holm G, et al.: Raloxifene does not affect insulin sensitivity or glycemic control in postmenopausal women with type 2 diabetes mellitus: a randomized clinical trial. J Clin Endocrinol Metab 2002, 87:122-128.
34. Chesnut CH 3rd, Silverman S, Andriano K, et al.: A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med 2000, 109:267-276.
35. Young AA, Wang MW, Gedulin B, et al.: Diabetogenic effects of salmon calcitonin are attributable to amylin-like activity. Metabolism 1995, 44:1581-1589.
36. Starke A, Keck E, Berger M, Zimmermann H: Effects of calcium and calcitonin on circulating levels of glucagon and glucose in diabetes mellitus. Diabetologia 1981, 20:547-552.
37. Black DM, Cummings SR, Karpf DB, et al.: Randomized trial of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348:1535-1541.
38. Harris ST, Watts NB, Genant HK, et al.: Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282:1344-1352.
39. Thiebaud D, Burckhardt P, Melchior J, et al.: Two years effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis Int 1994, 4:76-83.
40. Thiebaud D, Burckhardt P, Kriegbaum H, et al.: Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103:298-307.
41. Khan SA, Kanis JA, Vasikaran S, et al.: Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis. J Bone Miner Res 1997, 12:1700-1707.
42. Reid IR, Brown JP, Burckhardt P, et al.: Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002, 346:653-661.
43. Lindsay R, Cosman F, Lobo RA, et al.: Addition of alendronate to ongoing hormone replacement therapy in the treatment of osteoporosis: a randomized, controlled clinical trial. J Clin Endocrinol Metab 1999, 84:3076-3081.
44. Maugeri D, Panebianco P, Rosso D, et al.: Alendronate reduces the daily consumption of insulin (DCI) in patients with senile type I diabetes and osteoporosis. Arch Gerontol Geriatr 2002, 34:117-122.
45. Neer RM, Arnaud CD, Zanchetta JR, et al.: Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001, 344:1434-1441.
46. Mundy G, Garrett R, Harris S, et al.: Stimulation of bone formation in vitro and in rodents by statins. Science 1999, 286:1946-1949.
47. Bauer DC, Black DM, Van der Klift M: Statin use and fracture: a meta-analysis of 8 observational studies. Bone 2001, 28(suppl 1):S89.
48. Okazaki R, Toriumi M, Fukomoto S, et al.: Thiazolidinediones inhibit osteoclast-like cell formation and bone resorption in vitro. Endocrinology 1999, 140:5060-5065.
49. Okazaki R: Skeletal effects of thiazolidinediones [in Japanese]. Nippon Rinsho 2000, 58:456-460.